Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Raw Materials (2022 - 2025)

InMed Pharmaceuticals has reported Raw Materials over the past 4 years, most recently at $172200.0 for Q3 2025.

  • For Q3 2025, Raw Materials fell 37.26% year-over-year to $172200.0; the TTM value through Sep 2025 reached $172200.0, down 37.26%, while the annual FY2025 figure was $258300.0, 30.69% down from the prior year.
  • Raw Materials for Q3 2025 was $172200.0 at InMed Pharmaceuticals, down from $258300.0 in the prior quarter.
  • Over five years, Raw Materials peaked at $387071.0 in Q1 2023 and troughed at $172200.0 in Q4 2024.
  • A 4-year average of $250874.9 and a median of $233518.5 in 2022 define the central range for Raw Materials.
  • On a YoY basis, Raw Materials climbed as much as 78.55% in 2024 and fell as far as 49.23% in 2024.
  • Year by year, Raw Materials stood at $208737.0 in 2022, then changed by 0.0% to $208737.0 in 2023, then decreased by 17.5% to $172200.0 in 2024, then changed by 0.0% to $172200.0 in 2025.
  • Business Quant data shows Raw Materials for INM at $172200.0 in Q3 2025, $258300.0 in Q2 2025, and $258300.0 in Q1 2025.